THE JOINT CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.23 USD | +1.24% |
|
+0.41% | +27.26% |
| Mar. 07 | Transcript : The Joint Corp., Q4 2023 Earnings Call, Mar 07, 2024 | |
| Mar. 07 | Earnings Flash (JYNT) THE JOINT Reports Q4 Revenue $30.6M, vs. Street Est of $29.1M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- Low profitability weakens the company.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 277.95 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +27.26% | 181M | C+ | ||
| -14.92% | 84.68B | B- | ||
| +13.30% | 81.12B | C+ | ||
| +10.92% | 29.4B | C+ | ||
| -12.71% | 16.73B | B | ||
| -3.06% | 16.36B | A- | ||
| -2.63% | 14.92B | A- | ||
| -31.75% | 11.77B | - | - | |
| -1.42% | 11.72B | A- | ||
| +27.44% | 11.71B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- JYNT Stock
- Ratings The Joint Corp.
